Search results
Merck Reports Progress On The Cancer Front As It Prepares For Keytruda Patent Expiration
Benzinga via Yahoo Finance· 5 days agoAfter topping expectations with first quarter revenue and adjusted earnings last week, Merck & Co ...
Merck's KEYTRUDA shows survival benefit in gastric cancer trial By Investing.com
Investing.com· 6 days agoMerck & Co., Inc., a leading pharmaceutical company, announced positive results from the Phase 3...
Cerevance receives milestone payment under Alzheimer's collaboration with Merck
Seeking Alpha· 5 days agoPrivately held Cerevance receives milestone payment from Merck for Alzheimer's research...
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RSPH)?
Zacks via Yahoo Finance· 14 hours agoLooking at individual holdings, West Pharmaceutical Services Inc (WST) accounts for about 1.73% of...
15 Best Places to Retire in Florida That You’ve Never Heard Of
Insider Monkey via Yahoo Finance· 6 days agoThis article takes a look at the 15 best places to retire in Florida that you’ve never heard of. If...
Gossamer Bio and Chiesi Group to collaborate in therapy for lung condition
Reuters· 2 days agoGossamer Bio said on Monday it will collaborate with Italian drugmaker Chiesi Group to develop and...
Top 25 Stocks in the S&P 500 by Index Weight Right Now
Insider Monkey via Yahoo Finance· 5 days agoIn this piece, we will take a look at the top 25 stocks in the S&P 500 by index weight right now. If...
Moderna posts better-than-expected quarterly results as it looks to fall RSV vaccine launch
Market Watch· 6 days agoModerna Inc. on Thursday reported a narrower-than-expected first-quarter loss as the COVID vaccine...
Vanguard Health Care Fund's Strategic Moves in Q1 2024: A Focus on Pfizer Inc
GuruFocus.com via Yahoo Finance· 4 days agoThe top holdings were 8.97% in Eli Lilly and Co (NYSE:LLY), 6.45% in UnitedHealth Group Inc...
IDEAYA Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
FOX21 Colorado Springs· 15 hours agoASCO 2024 oral presentation of darovasertib neoadjuvant UM Phase 2 investigator-sponsored trial on June 3rd, and targeting neoadjuvant UM update in over 30 patients from Phase 2 company-sponsored ...